Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target
Eli Lilly and Company (NYSE: LLY) reported new long-term data from an open-label extension study...
Fineline Cube
BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia
BrainAurora Medical Technology Limited (HKG: 6681), China’s pioneer in neuroscience-AI integrated digital therapeutics, announced a...
UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa
UCB (EBR: UCB) announced National Medical Products Administration (NMPA) approval for Bimzelx (bimekizumab) in two...
Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11
Enhertu (trastuzumab deruxtecan), the HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (NYSE: AZN) and Daiichi...
FDA Approves Rocket Pharma’s Kresladi – First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
The U.S. Food and Drug Administration (FDA) this week approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel),...
C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market
C-Ray Therapeutics, a Chengdu-based radiopharmaceuticals specialist, announced a master radioisotope supply agreement with SHINE Technologies,...
Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes
Novo Nordisk (NYSE: NVO) announced FDA approval for Awiqli (insulin icodec), becoming the world’s first...
Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) received National Medical Products Administration (NMPA)...
CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline
CStone Pharmaceuticals (HKG: 2616) reported 2025 financial results, with annual sales declining 33.8% YoY to...
Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced clinical trial approval from China’s National...
Huadong Medicine’s HDM2024 Wins NMPA Approval – EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors
Huadong Medicine Co., Ltd. (SHE: 000963) announced clinical trial approval from China’s National Medical Products...
Biocytogen’s NEOK002 Wins FDA Approval for Phase I – EGFR/MUC1 Bispecific ADC Targets Solid Tumors
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced that NEOK Bio, Inc., its...
Joincare Pharma’s JKN2404 Wins NMPA Approval for Asthma Trial – Next-Gen Inhaled Corticosteroid Targets Improved Safety Profile
Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that JKN2404 inhalation suspension, a Category...
Grand Pharma 2025 Revenue HKD 12.28B – Innovative Products Hit 50% of Sales, Radiopharma Soars 61%
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) reported 2025 financial results, with revenue rising 5.5%...
Pulmongene’s PMG1015 Wins FDA Fast Track Designation – First-in-Class AREG Antibody Targets Idiopathic Pulmonary Fibrosis
Pulmongene (Beijing) Ltd. announced that PMG1015 received Fast Track Designation (FTD) from the U.S. Food...
China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years
China’s State Council issued “Opinions on Accelerating the Establishment of a Long-Term Care Insurance System”,...
Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%
Simcere Pharmaceutical Group (HKG: 2096) reported 2025 financial results, with revenue rising 16.5% YoY to...
GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market
GlaxoSmithKline (GSK; NYSE: GSK) formed a strategic alliance with SPH Keyuan Trade, a China pharmaceutical...
Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) announced National Medical Products Administration (NMPA) marketing approval for...
Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%
Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR...